Here are five insights:
1. The company hopes to receive clearance to test its cell therapy drug in a clinical trial.
2. The therapy, BRTX-100, is intended to treat chronic lower back pain caused by degenerative disc disease.
3. BRTX-100 includes autologous cultured mesenchymal stem cells from a patient’s bone marrow.
4. The product is designed for a non-surgical, intradiscal procedure performed in a physician’s office.
More articles on spine:
Drs. Kern Singh, Hyun Bae & more: 5 spine surgeons & neurosurgeons recently receiving honors — Jan. 9, 2017
Are infections associated with analgesic steroid paste after spinal decompression? 5 key notes
3 spine surgeons in the headlines — Jan. 6, 2017
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
